Download as pdf or txt
Download as pdf or txt
You are on page 1of 23

24/9/23, 21:56 Hematuria - ClinicalKey

CLINICAL OVERVIEW

Hematuria
Elsevier Point of Care (see details)
Updated May 27, 2022. Copyright Elsevier BV. All rights reserved.

Synopsis

Urgent Action 3
Patients with clot retention or gross hematuria with hemodynamic compromise may
require replacement of fluids and blood, correction of bleeding diathesis, reversal of
anticoagulants, and/or continuous bladder irrigation

Must identify source of bleeding; vascular phase CT is usually imaging study of choice

Cystoscopy may be required urgently if clots cannot be cleared by irrigation, urine


output is decreased, or bladder becomes distended

Rarely, uncontrolled bleeding from the bladder fails to respond to conservative therapy
and requires emergent cystectomy; uncontrolled bleeding from the kidney may require
nephrectomy or selective angiography and embolization

Key Points
Hematuria may present as macroscopic (gross) hematuria or microscopic hematuria and may
be symptomatic or asymptomatic

Gross hematuria is considered to be caused by malignancy until proven otherwise

Seek common causes of hematuria, including urinary tract infection, kidney calculi, and
infection-related glomerulonephritis (or IgA nephropathy)

https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-4046-8acd-1fedb4d030fd 1/23
24/9/23, 21:56 Hematuria - ClinicalKey

Use urinalysis to confirm hematuria (both macroscopic and microscopic) and to determine
whether blood has a glomerular (nephrologic) or nonglomerular (urologic) origin by
morphologic characteristics

Imaging is recommended to identify possible malignancy or urolithiasis and to evaluate


trauma. Selection of CT and/or ultrasonography is based on patient age and circumstances (eg,
symptoms suggesting urolithiasis, known or suspected trauma) and risk of malignancy 1

Cystoscopy is performed for all patients older than 35 years who have asymptomatic
microhematuria or unexplained gross hematuria and for patients of any age with risk factors
for malignancy 2
Treatment is directed toward the underlying cause of hematuria, once known; refer patient to
either urologist or nephrologist

Pitfalls
Routine therapy with warfarin or antiplatelet therapy usually does not cause microhematuria.
Evaluate patients on antiplatelet or anticoagulation therapy who have asymptomatic
microhematuria in the same way as other patients, regardless of type or level of anticoagulation
4

There is less risk of finding an abnormality in patients with anticoagulation and gross
hematuria than in patients with gross hematuria who do not have anticoagulation, but the risk
is present and these patients should be evaluated

Terminology

Clinical Clarification
Hematuria is the presence of an abnormal quantity of RBCs in the urine 5

Classification
Microscopic hematuria is the presence of 3 or more RBCs per high-power field in a single
properly collected, centrifuged urine specimen 6

Glomerular hematuria originates in the glomeruli 5

Nonglomerular hematuria originates from the renal pelvis, ureter, or bladder 5

https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-4046-8acd-1fedb4d030fd 2/23
24/9/23, 21:56 Hematuria - ClinicalKey

Macroscopic (gross) hematuria is urine that is discolored by blood, detectable by the naked eye
5

Diagnosis

Clinical Presentation

History
Symptoms at presentation

Microscopic or macroscopic hematuria can occur as an isolated finding, or it can be


accompanied by additional symptoms suggestive of its cause

Microscopic hematuria is often discovered incidentally, whereas gross hematuria usually


prompts an emergency department or urgent care visit

As little as 1 mL of blood in 1 L of urine will cause visible discoloration 5

Painless macroscopic hematuria is regarded as a symptom of cancer until proven otherwise

Macroscopic hematuria occurs in up to 85% of patients with bladder cancer and up to


40% of patients with renal cell carcinoma 7
Accompanying symptoms that can indicate underlying source or cause

Urinary tract infection symptoms, including:

Fever and chills

Dysuria

Suprapubic discomfort

Urinary frequency

Lower urinary tract irritative symptoms (eg, urgency, frequency, dysuria) often accompany
gross hematuria, regardless of its cause

Bleeding from other sites might indicate bleeding diathesis or coagulopathy

https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-4046-8acd-1fedb4d030fd 3/23
24/9/23, 21:56 Hematuria - ClinicalKey

Severe flank pain can indicate urolithiasis or pyelonephritis

Clots are almost always associated with a urologic origin

Portion of the urinary stream demonstrating gross hematuria during voiding gives clues about
location of bleeding within the urinary tract

Initial hematuria (start of voiding) indicates bleeding from the anterior urethra

Terminal hematuria (end of voiding) is consistent with bleeding from the posterior urethra,
bladder, trigone, or neck

Total hematuria (throughout voiding) indicates bleeding at or above bladder level

History can include any of the following:


Recent ingestion of certain foods or drugs, urinary instrumentation, vigorous exercise, or
current menstruation

Could indicate benign causes of hematuria or (in the case of certain foods or drugs)
discoloration that looks like (but is not) hematuria

Streptococcal cellulitis or upper respiratory tract infection associated with


glomerulonephritis

Precedes hematuria

Polycystic kidney disease or medullary sponge kidney

Conditions or diseases that cause hypercalciuria

Urinary tract endometriosis

Accompanies cyclic hematuria

Sickle cell trait or disease

More common in Black patients

Travel to the Middle East or Africa

Could indicate schistosomiasis

Patients with associated renal failure may have symptoms related to fluid overload (eg,
dyspnea, edema) or anemia (eg, palpitations, lightheadedness, fatigue)

https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-4046-8acd-1fedb4d030fd 4/23
24/9/23, 21:56 Hematuria - ClinicalKey

Consider common conditions that cause micro- or macroscopic hematuria first

Urinary tract infection (25% of all cases of atraumatic hematuria; 50% of cases in children)
(Related: Urinary Tract Infection in Adults) 7

Suprapubic discomfort (Related: Urinary Tract Infection in Children)

Urinary frequency
Dysuria

Urolithiasis (20% of all cases of atraumatic hematuria) (Related: Nephrolithiasis) 7

Acute onset of severe, colicky flank pain

Accompanied by nausea and vomiting


Uncommon conditions causing hematuria can be suggested by additional history

Infection-related glomerulonephritis (eg, postinfectious glomerulonephritis,


poststreptococcal glomerulonephritis)

Suggested by a recent skin or upper respiratory tract infection with hematuria after 10 to
21 days

IgA nephropathy is suggested if hematuria occurs earlier than 10 days after infection of the
upper respiratory tract or other infection (usually 1-2 days after infection develops)

Hypercalciuria in children (30% incidence in children with isolated hematuria [only


hematuria, no proteinuria]) 8

May be asymptomatic

Symptoms when present include frequency, urgency, incontinence, dysuria, and


abdominal and flank pain

Requires laboratory evaluation using spot urinary calcium to creatinine ratio

Physical examination
Examination results may be normal or may include findings specific to the underlying cause

Physical findings of common conditions that cause hematuria


Urinary tract infection

https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-4046-8acd-1fedb4d030fd 5/23
24/9/23, 21:56 Hematuria - ClinicalKey

Fever

Suprapubic or flank tenderness

Urolithiasis

Diaphoresis

Flank tenderness

Poststreptococcal glomerulonephritis (Related: Poststreptococcal Glomerulonephritis)

Flank or back tenderness from renal capsule swelling

Hypertension

Edema

Various findings associated with rare causes of hematuria 9

Hypertension: associated with nephritic syndrome and renal vascular disease

Edema and hypertension: consistent with glomerulonephritis and renal insufficiency

New cardiac murmur: suggests subacute bacterial endocarditis (risk factor for renal embolic
disease and immune complex glomerulonephritis)

Irregular heart rate of atrial fibrillation (risk factor for renal artery thrombosis/embolism)

Palpable flank or abdominal mass: can signify renal cancer

Enlarged or nodular prostate

Growth restriction with failure to thrive in children: possible chronic kidney disease

Causes and Risk Factors

Causes
Origin can be either glomerular or nonglomerular

Typically, microscopic hematuria is glomerular in origin and macroscopic hematuria is


nonglomerular (urologic)

https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-4046-8acd-1fedb4d030fd 6/23
24/9/23, 21:56 Hematuria - ClinicalKey

No cause is found in approximately 60% of patients 10

Most common causes of hematuria:

Urinary tract infection (Related: Urinary Tract Infection in Adults)

Bladder cancer (Related: Bladder Cancer)

Intrinsic renal disease (Related: Chronic Kidney Disease)

Urolithiasis (Related: Nephrolithiasis)

Most common causes of glomerular hematuria include IgA nephropathy and thin basement
membrane disease (Related: Sickle Cell Disease)

Causes of hematuria.

Glomerular

Primary glomerulonephritis
• Alport syndrome
• Thin basement membrane disease
• IgA nephropathy
• Pauci-immune (ANCA-related) vasculitis/anti–glomerular basement membrane disease
Secondary glomerulonephritis
• Henoch-Schönlein purpura
• Systemic lupus erythematosus
• Infection-related glomerulonephritis
• Thrombotic microangiopathies (eg, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome,
scleroderma renal crisis, malignant hypertension)
Associated with other glomerular pathology
• Diabetic nephropathy
• Focal segmental glomerular sclerosis
• Minimal change disease

https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-4046-8acd-1fedb4d030fd 7/23
24/9/23, 21:56 Hematuria - ClinicalKey

• Membranous nephropathy
Tubular/interstitial
• Interstitial nephritis
• Papillary necrosis
• Analgesic nephropathy
• Pyelonephritis
Structural kidney disease–related
• Acquired or hereditary cystic disease
• Medullary sponge kidney
Vascular

• Renal vein thrombosis


• Renal infarct/necrosis
• Arteriovenous malformations
• Nutcracker syndrome
Urothelial
• Malignancy (involving the kidney, ureters, bladder, or prostate)
• Nephrolithiasis
• Nephrocalcinosis
• Hypercalciuria
• Strictures
• Indwelling catheters
• Benign prostatic hypertrophy
• Bladder or ureteral polyps
Medications
• Cyclophosphamide/ifosfamide
• Anticoagulation associated
Other, not rare
• Infectious (pyelonephritis, cystitis, urethritis, prostatitis, schistosomiasis, tuberculosis, polyoma virus)
• Rejection or trauma in a kidney transplant

https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-4046-8acd-1fedb4d030fd 8/23
24/9/23, 21:56 Hematuria - ClinicalKey

• Pelvic radiation
• Bleeding disorders: sickle cell disease, sickle cell trait, hemophilia A or B, thrombocytopenia
• After instrumentation of the urinary tract or trauma
• Contamination from menstrual bleeding
Rare

• Endometriosis of the urinary tract


• Loin pain hematuria syndrome

Risk factors and/or associations

Age
Patients older than 35 years are at increased risk for the development of a urinary tract
malignancy 2

Sex
Males are at higher risk for hematuria to be caused by malignancy

Genetics
Hematuria may occur in association with several genetic disorders

Benign familial hematuria (OMIM #141200) 11

Autosomal dominant disorder manifested as nonprogressive isolated microscopic


hematuria that does not result in renal failure

Caused by heterozygous mutations in the COL4A3 or the COL4A4 genes, encoding alpha
chains for type IV collagen

Sickle cell disease (OMIM #603903) (Related: Sickle Cell Disease) 12 13

Autosomal recessive disorder characterized by intermittent vasoocclusive events and


chronic hemolytic anemia; micro- and macroscopic hematuria are common
manifestations of renal abnormalities

Caused by mutations in the HBB gene, encoding β-globin

https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-4046-8acd-1fedb4d030fd 9/23
24/9/23, 21:56 Hematuria - ClinicalKey

Alport syndrome 12 (OMIM #301050) 14

Most often an X-linked inherited disorder caused by mutations in COL4A5, encoding α-5
chain of type IV collagen

Hematuria during the first year of life and hearing loss in late childhood

Kidney calculi may be familial and may be linked to a specific gene (eg, X-linked
nephrolithiasis) (Related: Nephrolithiasis)

Other risk factors/associations


Common risk factors for urothelial malignancy in patients with hematuria

Occupational exposure to chemicals or dyes (benzenes or aromatic amines)


Past or current cigarette smoking

Overuse of analgesics (eg, aspirin, NSAIDs)

History of gross hematuria

History of pelvic irradiation

History of irritative voiding symptoms

History of urologic disorder

History of chronic urinary tract infection

History of chronic indwelling foreign body

Exposure to carcinogenic agents or chemotherapy (eg, alkylating agents)

Family history of urothelial cancer or Lynch syndrome 6

Antithrombotic medications may trigger hematuria (evaluation still required)

Among anticoagulants and antiplatelet agents, warfarin is associated with the greatest risk
but is unlikely to cause major hematuria 15

Novel antithrombotic agents (eg, dabigatran, rivaroxaban, apixaban) are more commonly
associated with major hematuria 15

https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-4046-8acd-1fedb4d030fd 10/23
24/9/23, 21:56 Hematuria - ClinicalKey

Diagnostic Procedures

Primary diagnostic tools


Dipstick testing may initially identify blood in the urine,
as it is sensitive enough to detect 1 to 2 RBCs per high-
power field when specimen is examined within 2 hours of
collection 5

Plasma proteins from hematuria may increase protein Asymptomatic microscopic


in the urine to less than 2+ on dipstick testing; hematuria (adult).
however, proteinuria of more than 2+ suggests
glomerular disease 16

Confirm heme-positive results of dipstick testing with


microscopic urinalysis before initiating further
evaluation 4 6
Visible hematuria propensity with
Voided midstream collection is sufficient for most individual anticoagulant or
(discard first 10 mL of urine) antiplatelet agents.

Catheterization may be necessary for the following:

Female patients with obesity

Patients with a Foley or suprapubic catheter

Menstruating patients
Patients who use intermittent catheterization Algorithm of the general approach
to the laboratory and radiologic
evaluation of the patient with
History and physical examination can provide clues to glomerular or extraglomerular
underlying cause of hematuria hematuria. - ANA, antinuclear
antibody; ASO, antistreptolysin O;
Assess risks for genitourinary malignancy, renal BUN, blood urea nitrogen; C3/C4,
disease, and gynecologic and nonmalignant complement; CBC, complete blood
cell count; Cr, creatinine; RBC, red
genitourinary causes 6 blood cell.

Most cases of microscopic and gross hematuria require


further evaluation 17

Cases of microscopic and gross hematuria that do


not require a complete workup, owing to high
https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-4046-8acd-1fedb4d030fd 11/23
24/9/23, 21:56 Hematuria - ClinicalKey

likelihood of a benign cause, include the following


(retest after resolution of the condition after a
minimum of 48 hours has elapsed): 2

Preexisting medical renal disease

Menstruation
Microscopic hematuria (pediatric).
Infection/viral illness

Trauma

Recent urologic procedures

Recent vigorous exercise


Evaluation of macroscopic
This exclusion has been challenged 18 hematuria (adult). - UTI, urinary
tract infection.
Finding of 25 RBCs or less per high-power field
in asymptomatic, low-risk females aged 35 to 50
years who are nonsmokers 19

Gross hematuria is considered to be caused by


malignancy until proven otherwise

If urinalysis and physical assessment results suggest a


glomerular cause of hematuria:

Obtain renal function panel, electrolyte levels, CBC,


erythrocyte sedimentation rate or C-reactive protein
level, and serologic tests for glomerular causes of
hematuria; also determine estimated GFR 16 20 21

Obtain throat culture and antistreptolysin O titers if


streptococcal infection is suspected 20

Ultrasonography of the kidneys is the imaging


procedure of choice in adults
Obtain anticoagulation studies on patients receiving
anticoagulants (eg, INR for warfarin therapy) 7

Additional evaluation in adults is based on risk


stratification as low, intermediate, or high risk for
genitourinary malignancy 6
https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-4046-8acd-1fedb4d030fd 12/23
24/9/23, 21:56 Hematuria - ClinicalKey

Low risk: either repeat urinalysis within 6 months or pr


ultrasonography

Intermediate risk: obtain cystoscopy and renal ultrasono

High risk: obtain cystoscopy and upper tract imaging (m


urography, or retrograde pyelography is combined with
renal ultrasonography)

Multiphasic CT urography with and without contrast


procedure of choice in high-risk adults to evaluate th
upper tracts 2
Ultrasonography of kidneys and bladder is typically the ini
regardless of suspected source

Laboratory

Imaging

Procedures

Other diagnostic tools 6

Differential Diagnosis
Causes of abnormal urine color other than blood

Red/brown color

Foods

Aloe

Beets
Blackberries

Fava beans

Rhubarb
https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-4046-8acd-1fedb4d030fd 13/23
24/9/23, 21:56 Hematuria - ClinicalKey

Medications

Antibiotics (eg, rifampin, metronidazole, nitrofurantoin, sulfonamides)

Antipyretics (eg, salicylates, ibuprofen)

Anticonvulsants (eg, phenytoin)

Laxatives (eg, phenolphthalein, senna)

Antimalarial agents (eg, quinine, chloroquine)

Tranquilizers/sedatives (eg, propofol, chlorpromazine, thioridazine, prochlorperazine)

Miscellaneous (phenazopyridine, methyldopa, levodopa, doxorubicin hydrochloride,


deferoxamine)
Other agents

Globins (eg, myoglobin, hemoglobin)

Porphyrin (eg, lead or mercury poisoning)

Orange

Foods

Carotene-containing foods (eg, carrots, winter squash)

Medications

Pyridium

β-carotene supplements

Vitamin B supplements

Rifampin

Warfarin

Other agents

Urochrome (breakdown product of hemoglobin, responsible for normal yellow color of


urine; dehydration deepens color)

https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-4046-8acd-1fedb4d030fd 14/23
24/9/23, 21:56 Hematuria - ClinicalKey

Green/blue

Foods

Asparagus

Medications

Amitriptyline

Cimetidine

Indomethacin

Promethazine

Black
Medications

Methyldopa

Treatment

Goals
Resolve bleeding

Disposition

Admission criteria
Criteria for general admission

Bladder outlet obstruction, particularly in the setting of either of the following:

Renal failure

Hydronephrosis

Hemodynamic instability
https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-4046-8acd-1fedb4d030fd 15/23
24/9/23, 21:56 Hematuria - ClinicalKey

Uncontrolled hypertension caused by renal parenchymal disease

Shock

Orthostatic hypotension

Other conditions, associated with the underlying cause

Severe or intractable pain

Severe nausea and vomiting

Severe anemia or bleeding condition

Recommendations for specialist referral


Urologist consultation or referral
Presence of clots

Confirmed gross hematuria, even if self-limited 4

Refer for cystoscopy and imaging those adults with microscopically confirmed hematuria
who do not have some demonstrable benign cause 4

Renal or ureteral calculi with the following:

Evidence of sepsis caused by urinary tract infection

Acute renal failure

Anuria

Intractable pain, nausea, or vomiting

Calculi larger than 10 mm

Hematuria in the presence of risk factors for malignancy

Nephrologist consultation or referral

Acute kidney injury 25

Increase in serum creatinine of 0.3 mg/dL or more

https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-4046-8acd-1fedb4d030fd 16/23
24/9/23, 21:56 Hematuria - ClinicalKey

Increase in serum creatinine of more than 50%

Reduction in urine output to less than 0.5 mL/kg/hour for 6 hours

Markedly diminished renal function of unknown duration (GFR less than 60 mL/minute)

Suspected glomerulonephritis

Treatment Options
Treatment is directed toward the underlying cause of hematuria, once it is identified

In the setting of clot retention or gross hematuria with hemodynamic compromise, 1 or more of
the following may be required: 3

IV fluid resuscitation

Packed RBC transfusion

Correction of clotting abnormalities

Urethral catheterization using a wide-bore (minimum 22-French), stiff, 3-way irrigating


catheter that allows continuous bladder irrigation with sterile water or saline

Source of bleeding must be identified; vascular phase CT is usually the imaging study of choice 3

Cystoscopy may be urgently required if clots cannot be cleared by irrigation, urine output is
decreased, or bladder becomes distended

Routine cystoscopy does not require antimicrobial prophylaxis in healthy adults in the absence
of infectious signs and symptoms 26

If indicated, empiric prophylactic antibiotic coverage with single dose of amoxicillin-


clavulanate or sulfamethoxazole-trimethoprim 26

Rarely, uncontrolled bleeding from the bladder fails to respond to conservative therapy, requiring
emergent cystectomy; uncontrolled bleeding from the kidney may require nephrectomy or
selective angiography and embolization 3

Nondrug and supportive care

Procedures

https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-4046-8acd-1fedb4d030fd 17/23
24/9/23, 21:56 Hematuria - ClinicalKey

Bladder irrigation 3

General explanation
A 3-way catheter is placed in the bladder

Lumen 1 allows for balloon inflation to keep the catheter in place

Lumen 2 provides a channel for instillation of saline or other fluid for irrigation

Lumen 3 allows outflow

Indication
Gross and persistent hematuria with hemodynamic impact

Clots resulting in urinary retention

Cystectomy 3

General explanation
Removal of all or part of the bladder, with construction of a urinary diversion

Extent of resection depends on cause of bleeding and presence (and depth) or absence of
malignancy

Indication
Intractable and uncontrollable bladder hemorrhage

Embolization 3

General explanation
Angiography is performed to localize the bleeding vessel, and a catheter is guided to the site to
deliver the embolus

Indication
https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-4046-8acd-1fedb4d030fd 18/23
24/9/23, 21:56 Hematuria - ClinicalKey

Refractory bleeding from the kidney with visualization of a culprit vessel amenable to
embolization

Nephrectomy 3

General explanation
Partial or complete resection of a kidney

Indication
Refractory, uncontrollable hematuria confirmed to originate from the kidney

Monitoring
After a negative urologic workup, repeat urinalysis within 12 months 6

If that urinalysis is negative, may stop monitoring

If urinalysis is persistently positive for hematuria, engage in shared decision making


regarding ongoing evaluation

If patients with negative findings on prior hematuria evaluation develop gross hematuria,
significant increase in degree of microscopic hematuria, or new urologic symptoms, initiate
further evaluation

Complications and Prognosis

Prognosis
Variable

Persistent asymptomatic isolated microscopic hematuria in patients aged 16 to 25 years is


associated with increased risk of end-stage renal disease for 22 years, although incidence and
absolute risk are low 27

Urinary tract malignancy rate for microscopic hematuria is greater than 2% 24

The earlier bladder cancer is detected, the better the prognosis (stage I 5-year survival is
88%, whereas stage IV 5-year survival is 15%) 24

https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-4046-8acd-1fedb4d030fd 19/23
24/9/23, 21:56 Hematuria - ClinicalKey

Urinary tract malignancy rate for gross hematuria is 25% 28

References
1. American College of Radiology: ACR Appropriateness Criteria: Hematuria--Child. ACR website. Revised
2018. Accessed January 21, 2022. https://acsearch.acr.org/docs/69440/Narrative/
View In Article (https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-
4046-8acd-1fedb4d030fd#inline-reference-1) | Cross Reference (https://acsearch.acr.org/docs/69440/Narrative/)

2. Davis R et al: Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA
guideline. J Urol. 188(6 suppl):2473-81, 2012
View In Article (https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-
4046-8acd-1fedb4d030fd#inline-reference-2) | Cross Reference (https://pubmed.ncbi.nlm.nih.gov/23098784)

3. Fragkopoulou C et al: Haematuria. Surgery (Oxford). 31(10):509-15, 2013


View In Article (https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-
4046-8acd-1fedb4d030fd#inline-reference-3) | Cross Reference (https://doi-
org.uandes.idm.oclc.org/10.1016/j.mpsur.2013.08.005)

4. Nielsen M et al: Hematuria as a marker of occult urinary tract cancer: advice for high-value care from the
American College of Physicians. Ann Intern Med. 164(7):488-97, 2016
View In Article (https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-
4046-8acd-1fedb4d030fd#inline-reference-4) | Cross Reference (https://pubmed.ncbi.nlm.nih.gov/26810935)

5. Jimbo M: Evaluation and management of hematuria. Prim Care. 37(3):461-72, vii, 2010
View In Article (https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-
4046-8acd-1fedb4d030fd#inline-reference-5) | Cross Reference (https://pubmed.ncbi.nlm.nih.gov/20705193)

6. Barocas DA et al: Microhematuria: AUA/SUFU guideline. J Urol. 204(4):778-86, 2020


View In Article (https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-
4046-8acd-1fedb4d030fd#inline-reference-6) | Cross Reference (https://pubmed.ncbi.nlm.nih.gov/32698717)

7. Sokolosky MC: Hematuria. Emerg Med Clin North Am. 19(3):621-32, 2001
View In Article (https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-
4046-8acd-1fedb4d030fd#inline-reference-7) | Cross Reference (https://pubmed.ncbi.nlm.nih.gov/11554278)

8. Parekh DJ et al: The association of an increased urinary calcium-to-creatinine ratio, and asymptomatic
gross and microscopic hematuria in children. J Urol. 167(1):272-4, 2002
View In Article (https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-
4046-8acd-1fedb4d030fd#inline-reference-8) | Cross Reference (https://pubmed.ncbi.nlm.nih.gov/11743337)

9. Margulis V et al: Assessment of hematuria. Med Clin North Am. 95(1):153-9, 2011
https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-4046-8acd-1fedb4d030fd 20/23
24/9/23, 21:56 Hematuria - ClinicalKey

View In Article (https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-


4046-8acd-1fedb4d030fd#inline-reference-9) | Cross Reference (https://pubmed.ncbi.nlm.nih.gov/21095418)

10. Bryant RJ et al: Haematuria. Surgery (Oxford). 26(4):150-3, 2008


View In Article (https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-
4046-8acd-1fedb4d030fd#inline-reference-10) | Cross Reference (https://doi-
org.uandes.idm.oclc.org/10.1016/j.mpsur.2008.02.003)

11. Hematuria, Benign Familial; BFH. Online Mendelian Inheritance in Man. OMIM website. Johns
Hopkins University. Updated May 27, 2010. Edited June 21, 2016. Accessed January 21, 2022.
https://www.omim.org/entry/141200
View In Article (https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-
4046-8acd-1fedb4d030fd#inline-reference-11) | Cross Reference (https://www.omim.org/entry/141200)

12. Kazi SN et al: Work-up of hematuria. Prim Care. 41(4):737-48, 2014


View In Article (https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-
4046-8acd-1fedb4d030fd#inline-reference-12) | Cross Reference (https://pubmed.ncbi.nlm.nih.gov/25439531)

13. Sickle Cell Anemia. Online Mendelian Inheritance in Man. OMIM website. Johns Hopkins University.
Updated March 8, 2021. Edited March 8, 2021. Accessed January 21, 2022.
https://www.omim.org/entry/603903
View In Article (https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-
4046-8acd-1fedb4d030fd#inline-reference-13) | Cross Reference (https://www.omim.org/entry/603903)

14. Alport Syndrome 1, X-Linked; ATS1. Online Mendelian Inheritance in Man. OMIM website. Johns
Hopkins University. Updated July 10, 2015. Edited August 2, 2019. Accessed January 21, 2022.
https://www.omim.org/entry/301050
View In Article (https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-
4046-8acd-1fedb4d030fd#inline-reference-14) | Cross Reference (https://www.omim.org/entry/301050)

15. Bhatt NR et al: Incidence of visible hematuria among antithrombotic agents: a systematic review of over
175,000 patients. Urology. 114:27-32, 2018
View In Article (https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-
4046-8acd-1fedb4d030fd#inline-reference-15) | Cross Reference (https://pubmed.ncbi.nlm.nih.gov/29191640)

16. Pan CG: Evaluation of gross hematuria. Pediatr Clin North Am. 53(3):401-12, vi, 2006
View In Article (https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-
4046-8acd-1fedb4d030fd#inline-reference-16) | Cross Reference (https://pubmed.ncbi.nlm.nih.gov/16716787)

17. Linder BJ et al: Guideline of guidelines: asymptomatic microscopic haematuria. BJU Int. 121(2):176-83,
2018
View In Article (https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-
4046-8acd-1fedb4d030fd#inline-reference-17) | Cross Reference (https://pubmed.ncbi.nlm.nih.gov/28921833)

https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-4046-8acd-1fedb4d030fd 21/23
24/9/23, 21:56 Hematuria - ClinicalKey

18. Akiboye RD et al: Haematuria in sport: a review. Eur Urol Focus. 5(5):912-6, 2019
View In Article (https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-
4046-8acd-1fedb4d030fd#inline-reference-18) | Cross Reference (https://pubmed.ncbi.nlm.nih.gov/29500137)

19. American College of Obstetricians and Gynecologists et al: Committee Opinion No. 703: asymptomatic
microscopic hematuria in women. Obstet Gynecol. 129(6):e168-72, 2017
View In Article (https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-
4046-8acd-1fedb4d030fd#inline-reference-19) | Cross Reference (https://pubmed.ncbi.nlm.nih.gov/28368896)

20. Hahn RG et al: Evaluation of poststreptococcal illness. Am Fam Physician. 71(10):1949-54, 2005
View In Article (https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-
4046-8acd-1fedb4d030fd#inline-reference-20) | Cross Reference (https://pubmed.ncbi.nlm.nih.gov/15926411)

21. Thaller TR et al: Evaluation of asymptomatic microscopic hematuria in adults. Am Fam Physician.
60(4):1143-52, 1154, 1999
View In Article (https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-
4046-8acd-1fedb4d030fd#inline-reference-21) | Cross Reference (https://pubmed.ncbi.nlm.nih.gov/10507744)

22. Niyyar VD et al: Point-of-care ultrasound in the practice of nephrology. Kidney Int. 93(5):1052-9, 2018
View In Article (https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-
4046-8acd-1fedb4d030fd#inline-reference-22) | Cross Reference (https://pubmed.ncbi.nlm.nih.gov/29477241)

23. American College of Radiology: ACR Appropriateness Criteria: Hematuria. ACR website. Revised 2019.
Accessed January 21, 2022. https://acsearch.acr.org/docs/69490/Narrative/
View In Article (https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-
4046-8acd-1fedb4d030fd#inline-reference-23) | Cross Reference (https://acsearch.acr.org/docs/69490/Narrative/)

24. Pal A et al: Hematuria evaluation in the hospitalized patient. Hosp Med Clin. 2(1):e57-71, 2013
View In Article (https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-
4046-8acd-1fedb4d030fd#inline-reference-24) | Cross Reference (https://doi-
org.uandes.idm.oclc.org/10.1016/j.ehmc.2012.07.001)

25. Kellum JA et al: Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (part
1). Crit Care. 17(1):204, 2013
View In Article (https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-
4046-8acd-1fedb4d030fd#inline-reference-25) | Cross Reference (https://pubmed.ncbi.nlm.nih.gov/23394211)

26. American Urological Association: Best Practice Statement on Urologic Procedures and Antimicrobial
Prophylaxis. AUA website. Published June 2019. Accessed January 21, 2022.
https://www.auanet.org/guidelines/guidelines/urologic-procedures-and-antimicrobial-prophylaxis-(2019)
View In Article (https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-
4046-8acd-1fedb4d030fd#inline-reference-26) | Cross Reference
(https://www.auanet.org/guidelines/guidelines/urologic-procedures-and-antimicrobial-prophylaxis-(2019))

https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-4046-8acd-1fedb4d030fd 22/23
24/9/23, 21:56 Hematuria - ClinicalKey

27. Vivante A et al: Persistent asymptomatic isolated microscopic hematuria in Israeli adolescents and young
adults and risk for end-stage renal disease. JAMA. 306(7):729-36, 2011
View In Article (https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-
4046-8acd-1fedb4d030fd#inline-reference-27) | Cross Reference (https://pubmed.ncbi.nlm.nih.gov/21846854)

28. Alishahi S et al: Haematuria investigation based on a standard protocol: emphasis on the diagnosis of
urological malignancy. J R Coll Surg Edinb. 47(1):422-7, 2002
View In Article (https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-
4046-8acd-1fedb4d030fd#inline-reference-28) | Cross Reference (https://pubmed.ncbi.nlm.nih.gov/11874263)

(https://play.google.com/store/apps/details?id=com.elsevier.cs.ck&hl=en)
(https://itunes.apple.com/us/app/clinicalkey/id1041998175) (https://www.facebook.com/ClinicalKey)
(https://www.linkedin.com/company/3969981) (https://www.twitter.com/ClinicalKey)

(https://www.elsevier.com/)

Contact Us (https://service-elsevier-com.uandes.idm.oclc.org/app/contact/supporthub/clinicalkey/)

Resource Center (https://elsevierresources.com/clinicalkey/resource-centers/)

Registered User Agreement (http://www.elsevier.com.uandes.idm.oclc.org/legal/elsevier-registered-user-agreement)

Help (https://service-elsevier-com.uandes.idm.oclc.org/app/home/supporthub/clinicalkey/)

Terms & Conditions (https://www.elsevier.com/legal/elsevier-website-terms-and-conditions)

Privacy Policy (http://www.elsevier.com/legal/privacy-policy)

Accessibility (https://www.elsevier.com/about/accessibility)

We use cookies to help provide and enhance our service and tailor content. By continuing you agree to the
Configuración de cookies .
Copyright © 2023 Elsevier B.V. or its licensors or contributors.

(https://www.relx.com/)

https://www-clinicalkey-com.uandes.idm.oclc.org/#!/content/clinical_overview/67-s2.0-54490e0e-c9b7-4046-8acd-1fedb4d030fd 23/23

You might also like